| Income statement (USD) | Q2 2026 ended Jun 30, 2026 | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.97B | 19.80B | 19.29B | 17.60B | 15.56B | 12.73B | 13.53B | 11.44B |
| Cost of revenue | 3.27B | 3.58B | 3.37B | 3.01B | 2.45B | 2.23B | 2.40B | 2.17B |
| Gross profit | 19.71B | 16.22B | 15.92B | 14.59B | 13.11B | 10.50B | 11.13B | 9.27B |
| Research and development | 3.82B | 3.51B | 3.80B | 3.47B | 3.34B | 2.73B | 3.02B | 2.73B |
| Selling, general and admin | 3.43B | 2.93B | 3.13B | 2.74B | 2.75B | 2.47B | 2.42B | 2.10B |
| Interest expense | 222.60M | 179.60M | 249.00M | 243.70M | 225.10M | 192.70M | ||
| Income before tax | 9.25B | 8.85B | 8.27B | 7.23B | 6.78B | 3.46B | 5.04B | 1.59B |
| Income tax | 2.15B | 1.45B | 1.63B | 1.65B | 1.12B | 697.00M | 628.50M | 618.10M |
| Net income | 7.09B | 7.40B | 6.64B | 5.58B | 5.66B | 2.76B | 4.41B | 970.30M |
| EPS | 7.95 | 8.27 | 7.40 | 6.22 | 6.30 | 3.07 | 4.90 | 1.08 |
| EPS (diluted) | 7.94 | 8.26 | 7.39 | 6.21 | 6.29 | 3.06 | 4.88 | 1.07 |
| Diluted shares | 893.70M | 895.90M | -400.0K | 898.80M | 899.80M | 900.60M | -300.0K | 905.00M |
| Dividends per share | 3.46 | 3.23 | 0.00 | 3.00 | 2.80 | 0.00 |
From Eli Lilly's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.